Reviva Pharmaceuticals Holdings, Inc. Common Stock
RVPHReviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. Founded to leverage its expertise in drug discovery and development, Reviva aims to address unmet medical needs through innovative solutions. The company's pipeline includes candidates targeting conditions such as depression, anxiety, and other neuropsychiatric disorders.
Company News
Reviva Pharmaceuticals Holdings, Inc. announced that its Founder, President, and CEO Laxminarayan Bhat will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco. The late-stage biopharmaceutical company is developing therapies for CNS, inflammatory, and cardiometabolic diseases, with two main drug ca...
Reviva Pharmaceuticals will present research data on brilaroxazine's treatment effects on negative symptoms in schizophrenia patients at the CNS Summit 2025 in Boston, Massachusetts.
Reviva Pharmaceuticals announced a public offering of 27 million shares and accompanying warrants, raising approximately $9 million to fund research and development activities and working capital.
The schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.
Reviva Pharmaceuticals Holdings, Inc. (RVPH), a late-stage pharmaceutical company, announced that its Founder, President, and CEO will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, focusing on tackling mental health through new targets and endpoints progress.
